Combination of EGFR signalling pathway inhibitors and prevention of resistance. by Cornelissen, B

Imaging the inside of a tumour: a review of radionuclide imaging and theranostics targeting intracellular epitopes. by Cornelissen, B

Bioorthogonal chemistry: implications for pretargeted nuclear (PET/SPECT) imaging and therapy. by Knight, J, Cornelissen, B

Emerging chelators for nuclear imaging by Sneddon, D, Cornelissen, B

Targeting the nucleus: an overview of Auger-electron radionuclide therapy. by Cornelissen, B, Vallis, K

Targeting the tumour: Cell penetrating peptides for molecular imaging and radiotherapy by Kersemans, V, Cornelissen, B

Preservation of ligand functionality by click chemistry by Cornelissen, B, Knight, JC

Imaging the DNA damage response with PET and SPECT by Knight, J, Koustoulidou, S, Cornelissen, B

Cell penetrating peptides for in vivo molecular imaging applications. by Kersemans, V, Kersemans, K, Cornelissen, B

PARP inhibitors in cancer diagnosis and therapy by Chan, C, Tan, KV, Cornelissen, B

Imaging DNA damage response (DDR) during oncogenesis by Cornelissen, B, Able, S, Kersemans, V, Vallis, K

Microscale radiolabelling of antibodies with zirconium-89 for positron emission tomography by Knight, J, Paisey, S, Marshall, C, Cornelissen, B

DNA double-strand break repair: a theoretical framework and its application by Murray, P, Cornelissen, B, Vallis, K, Chapman, S

Imaging of pancreatic tumours in mice using radiolabelled anti-Claudin4 antibodies by Mosley, M, Knight, J, Koustoulidou, S, Cornelissen, B

Molecular radiotherapy using cleavable radioimmunoconjugates that target EGFR and γH2AX. by Cornelissen, B, Waller, A, Able, S, Vallis, K

Combination strategies to improve targeted radionuclide therapy by Chan, T, O'Neill, E, Habjan, C, Cornelissen, B

PET and SPECT imaging for the acceleration of anti-cancer drug development by Hillyar, C, Knight, J, Vallis, K, Cornelissen, B

Closing the gap between 19F and 18F chemistry by Ajenjo, J, Destro, G, Cornelissen, B, Gouverneur, V

Can γH2AX be used to personalise cancer treatment? by Shah, K, Cornelissen, B, Kiltie, A, Vallis, K

Indium-111 labeled anti-CD33 monoclonal antibodies (mAbs) modified with nuclear-localizing sequences (NLS) kill mitoxantrone-resistant HL-60 acute myelogenous leukemia (AML) cells by Kersemans, V, Cornelissen, B, Dick, J, Reilly, R